Three experimental Ebola vaccines are moving into advanced trials, with British researchers playing a central role. Sources close to the UK Health Security Agency confirm that the vaccines, developed by Oxford University and the Jenner Institute, are being fast-tracked as the World Health Organisation reports a surge in cases in Uganda and the Democratic Republic of Congo. Documents obtained by this newsroom show that the UK government has allocated £12m to expand production capacity, despite a broader freeze on overseas aid spending.
The move comes as the WHO warns that the current outbreak strain, the Sudan variant, has a fatality rate of up to 70% and is showing signs of drug resistance. One of the trial leads, speaking on condition of anonymity, said: 'We are working around the clock. This is a race against time, and the clock is ticking.
' The trials will involve 5,000 volunteers across sites in Uganda, Kenya, and the UK. Critics inside the scientific community, however, warn that the accelerated timeline compromises safety protocols. One anonymous researcher told this reporter: 'They are pushing this through without the normal checks.
If something goes wrong, it will be a disaster.' The pharmaceutical giant GSK, which owns the original Ebola vaccine license, has refused to waive patent protections, a decision that has drawn fire from lawmakers. Labour MP Preet Kaur Gill called it 'a moral disgrace' in a parliamentary question yesterday.
Meanwhile, the UK's Medicines and Healthcare products Regulatory Agency has deployed a specialist team to Uganda to oversee the trials. This newsroom has learned that the team includes former military biodefence personnel. The situation is fluid.
What is clear is that the intersection of corporate greed, government expediency, and viral evolution is a volatile compound. I'll be tracking this story closely. Follow the money.
Follow the bodies.
